Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Shree Ganesh Biotech (India) L · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Shree Ganesh Biotech (India) L
BSE: 539470
BSE: 539470
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
Shree Ganesh Biotech (India) L
StateQ4 FY26 filed
Last close · 28 Oct 2026₹0.46
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA23.0 · 0.29 · 35.6
Shree Ganesh Biotech (India) L is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 73 | 62 | 20 | 23 | 5 |
| EBITDA (ex other income) | 3 | 2 | (0) | (1) | (1) |
| margin % | 4.7 | 3.4 | (1.0) | (4.6) | (19.3) |
| Owners' profit | 3 | 2 | 1 | 0 | 0 |
| EPS, as reported (₹) | 0.13 | 0.05 | 0.02 | 0.01 | 0.01 |
| ROE % · ROCE % | 4.2 · 5.8 | 3.3 · 4.4 | 1.0 · 1.4 | 0.4 · 0.6 | 0.6 · 0.8 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 0 | (3) | 10 | (10) | (8) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Shree Ganesh Biotech (India) L · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 2 | 14 | 3 | 1 | 1 | 1 | 2 |
| Profit before tax | 0 | 0 | 1 | (1) | 0 | 0 | 0 | (0) |
| Net profit | 0 | 0 | 1 | (1) | 0 | 0 | 0 | (0) |
| EPS (₹) | 0.01 | 0.01 | 0.02 | (0.02) | 0.01 | 0.00 | 0.01 | 0.00 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ANTHEM BIOSCIENCES LTD | 46,905 | 121.2 | 15.42 | 48.4 | 19.5 | 26.6 | — | 42.0 |
| ADVANCED ENZYME TECH LTD | 2,932 | 17.7 | 1.74 | 10.3 | 10.3 | 13.4 | 8.2 | 33.7 |
| CCME GLOBAL LIMITED | 144 | 93.9 | 3.61 | — | (1.8) | (1.8) | — | — |
| VIVO BIO TECH LTD. | 31 | 3.2 | 0.33 | 4.5 | (1.8) | 3.2 | 0.6 | 31.5 |
| Shree Ganesh Biotech (India) L ◆ | 18 | 23.0 | 0.29 | — | 0.6 | 0.8 | — | (7.0) |
| GENOMIC VALLEY BIOTECH LIMITED | 13 | 363.6 | 3.39 | — | 0.8 | 1.0 | — | 40.5 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 23.0 | 30.8 | 62 of 164 | 63% |
| P/B | 0.3 | 3.1 | 4 of 169 | 98% |
| ROCE | 0.8 | 10.7 | 154 of 189 | 19% |
| ROE | 0.6 | 9.5 | 142 of 172 | 18% |
| Debt / Equity | 0.0 | 0.1 | 1 of 172 | 78% |
| EBITDA margin | (7.0) | 17.7 | 163 of 170 | 4% |
| Revenue growth | (29.4) | 15.3 | 151 of 166 | 9% |
| Profit growth | 84.2 | 30.0 | 41 of 164 | 76% |
| Market cap | 18 | 798 | 171 of 187 | 9% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Shree Ganesh Biotech (India) L · 29 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · Board meeting to approve second-quarter and half-year results | results | low | — | — |
| 6 Oct 2026 · Reg 74(5) Compliance Certificate Filing for Q2 FY27 | compliance | minimal | — | — |
| 28 Sept 2026 · AGM voting results: both resolutions passed | board shareholder meetings | low | — | — |
| 28 Sept 2026 · Proceedings of 16th AGM held on September 28, 2026 | board shareholder meetings | low | — | — |
| 17 Sept 2026 · Trading window closed from Oct 1 for Q2 results | compliance | minimal | — | — |
| 3 Sept 2026 · Annual Report FY26 submitted; 16th AGM on Sept 28, 2026 | compliance | low | — | — |
| 3 Sept 2026 · Book closure for AGM from September 21 to 28, 2026 | corporate actions | low | — | — |
| 3 Sept 2026 · Notice of 16th AGM on 28 September 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Company website updated to new domain | compliance | minimal | — | — |
| 4 Aug 2026 · Nil statement on use of issue proceeds for Q1 FY27 | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in